Dimetacrine (brand names Istonil, Istonyl, Linostil, Miroistonil), also known as dimethacrine and acripramine, is a tricyclic antidepressant (TCA) used in Europe and formerly in Japan for the treatment of depression. It has imipramine-like effects; though, in a double-blindclinical trial against imipramine, dimetacrine was found to have lower efficacy in comparison and produced more weight loss and abnormal liver tests. Little is known about the pharmacology of dimetacrine, but it can be inferred that it acts in a similar manner to other TCAs. If this is indeed the case, dimetacrine may induce severe cardiac toxicity in overdose (a side effect unique to the tricyclic class of antidepressants).
^José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN3-527-31058-4.
^Taen S, Pöldinger W (December 1966). "[Dimethacrine (istonil), an acridane derivative with the antidepressive action]". Schweizerische Medizinische Wochenschrift (in German). 96 (48): 1616–20. PMID6008540.
^Meyer R (May 1968). "[Contribution to the clinical evaluation of the antidepressive effect of dimethacrine (Istonil)]". Praxis (in German). 57 (20): 721–3. PMID5756370.
^Abuzzahab FS (November 1973). "A double-blind investigation of dimethacrine versus imipramine in hospitalized depressive states". International Journal of Clinical Pharmacology, Therapy and Toxicology. 8 (3): 244–53. PMID4149236.